MVASI, (bevacizumab-awwb), Sterile Ophthalmic Solution for Injection, 3.25mg/0.13mL (25 mg/mL) 0.13 mL per syringe, Dose: 1.25mg/0.05mL, Single Use Syringe For Intraocular Injection, Edge Pharma, LLC, 856 Hercules Dr. Colchester, VT 05446, NDC 05446-1661-13
Published February 2, 2022 · Recall initiated: December 6, 2021
Summary
FDA records drug Class II recall D-0412-2022, published February 2, 2022 and initiated December 6, 2021. Recalling firm: Edge Pharma, LLC; Status: Terminated; Reported quantity: 199 syringes; Lot: 11-2021-01@2 12/15/2021. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Lack of Assurance of Sterility
What to do
Voluntary: Firm initiated · Press Release
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Edge Pharma, LLC
- Distributor
- nationwide
- Lot
- 11-2021-01@2 12/15/2021
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDAEdetate Disodium (EDTA), Sterile Ophthalmic Solution, (PF) 3%, 10mL per dropper, Single Dose Droptainer forFebruary 2, 2022
- FDAPhenol, Topical Solution (PF) Multiple Dose Vial, 89%, 3 mL per vial, Edge Pharma, LLC, 856 Hercules Dr.,February 2, 2022
- FDAProfound-PE Dental Gel, Lidocaine HCl/Prilocaine HCl/Tetracaine HCl/Phenylephrine, 10% / 10% / 4% / 2%,February 2, 2022
- FDAEdetate Disodium (EDTA), Sterile Ophthalmic Solution (PF) 1.5%, 10 mL per dropper, Single Dose Droptainer forFebruary 2, 2022
- FDANeostigmine methylsulfate, 5 mg/5mL (1 mg/mL), 5 mL per syringe, Single Use Syringe for IV or IM Injection,February 2, 2022
- FDAPhenol, Sterile Solution for Injection (PF), 6%, 5 mL per vial, Single Use Vial for Perineural Injection, EdgeFebruary 2, 2022
Questions about this recall
Was MVASI, (bevacizumab-awwb), Sterile Ophthalmic Solution for Injection, 3.25mg/0.13mL (25 mg/mL) 0.13 mL per syringe, Dose: 1.25mg/0.05mL, Single Use Syringe For Intraocular Injection, Edge Pharma, LLC, 856 Hercules Dr. Colchester, VT 05446, NDC 05446-1661-13 recalled?
Yes. FDA published recall D-0412-2022 on February 2, 2022. Reported hazard: Lack of Assurance of Sterility
What should I do if I have this product?
Voluntary: Firm initiated · Press Release